Korsana Biosciences (KRSA) Registration filing summary

Company overview and business model

• Biopharmaceutical business focused on treatments for serious diseases; shifted strategy toward acquiring or licensing non-sGC assets, mainly in CNS, and developing them through outsourced research, development and manufacturing.

• Retained olinciguat, which management is seeking to out-license, and praliciguat, which is out-licensed; sold zagociguat and CY3018 assets to Tisento in July 2023.

• The 2023 Tisento transaction included $8.0M cash, $2.4M reimbursement of specified operating expenses and 10% of Tisento’s parent equity at closing.

Financial performance and metrics

• As of Feb. 3, 2025: 2,710,096 common shares and 351,037 Series A preferred shares outstanding; non-affiliate public float was 2,120,740 shares, valued at $11.3M using $5.32 per share.

• Common stock closed at $5.32 on Feb. 3, 2025; the shelf is subject to a one-third-of-public-float sales limit in any 12-month period while public float remains below $75M.

Use of proceeds and capital allocation

• Net proceeds intended for general corporate purposes, including clinical trials, R&D, G&A, potential partnerships or acquisitions, and technology acquisitions or licenses; offering-specific use may be revised in a supplement.

• Strategy aims to identify suitable assets and secure capital, capabilities and transactions to advance current and future assets; further R&D funding is part of the plan.